Literature DB >> 18242705

Ovine anti-rabies antibody production and evaluation.

El-Rashdy M Redwan1, Ali Fahmy, Amr El Hanafy, Nawal Abd El-Baky, Sobhy M A Sallam.   

Abstract

In view of the disadvantages of human and equine rabies immunoglobulin still there is urgent needs for safe and cost-control anti-rabies immunoglobulins especially for person who have been severely exposed (categories III) to the virus. Our attempt to produce a less immunogenic and cheaper anti-rabies immunoglobulin affordable for those people living in developing countries, has been harnessed the ovine as a bioreactor instead the horse. The animals have been intramuscular immunized, and the plasma processed with 5% caprylic acid to yield IgG with purity of 95%. Moreover, antibody apparently indicated that the titer and neutralizing indexes were harmonized, especially at higher antibody dilution. The results showed that three immunized sheep were produced about 7000 IU of purified anti-rabies antibody. Sheep's IgG has low immunogenic effect than human and horse antibodies when injected into the mouse. Pure concentrated ovine antibody may serve as a possible alternative to currently available anti-rabies human or equine immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18242705     DOI: 10.1016/j.cimid.2007.11.004

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  8 in total

1.  Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.

Authors:  Stephen Findlay-Wilson; Linda Easterbrook; Sandra Smith; Neville Pope; Gareth Humphries; Holger Schuhmann; Didier Ngabo; Emma Rayner; Ashley David Otter; Tom Coleman; Bethany Hicks; Victoria Anne Graham; Rachel Halkerston; Kostis Apostolakis; Stephen Taylor; Susan Fotheringham; Amanda Horton; Julia Anne Tree; Matthew Wand; Roger Hewson; Stuart David Dowall
Journal:  Antiviral Res       Date:  2022-05-06       Impact factor: 10.103

2.  Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma.

Authors:  Esmail M El-Fakharany; Nawal Abedelbaky; Bakry M Haroun; Lourdes Sánchez; Nezar A Redwan; Elrashdy M Redwan
Journal:  Virol J       Date:  2012-09-16       Impact factor: 4.099

3.  Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine.

Authors:  Xinjian Liu; Hong Lin; Qi Tang; Chen Li; Songtao Yang; Zhongcan Wang; Changjun Wang; Qing He; Brian Cao; Zhenqing Feng; Xiaohong Guan; Jin Zhu
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

Review 4.  Hib Vaccines: Past, Present, and Future Perspectives.

Authors:  Adi Essam Zarei; Hussein A Almehdar; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-01-20       Impact factor: 4.818

5.  Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection.

Authors:  Stuart David Dowall; Jo Callan; Antra Zeltina; Ibrahim Al-Abdulla; Thomas Strecker; Sarah K Fehling; Verena Krähling; Andrew Bosworth; Emma Rayner; Irene Taylor; Sue Charlton; John Landon; Ian Cameron; Roger Hewson; Abdulsalami Nasidi; Thomas A Bowden; Miles W Carroll
Journal:  J Infect Dis       Date:  2015-12-28       Impact factor: 5.226

6.  Influence of camel milk on the hepatitis C virus burden of infected patients.

Authors:  Esmail Mohamad El-Fakharany; Nawal Abd El-Baky; Mustafa Hassan Linjawi; Abdullah Abdelhafiz Aljaddawi; Tahya Hussein Saleem; Ahmed Yassine Nassar; Ashraf Osman; Elrashdy Moustafa Redwan
Journal:  Exp Ther Med       Date:  2017-02-22       Impact factor: 2.447

7.  Simple and efficient protocol for immunoglobulin Y purification from chicken egg yolk.

Authors:  Elrashdy M Redwan; Abdullah A Aljadawi; Vladimir N Uversky
Journal:  Poult Sci       Date:  2020-12-24       Impact factor: 3.352

8.  An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Authors:  Natalie E Stevens; Cara K Fraser; Mohammed Alsharifi; Michael P Brown; Kerrilyn R Diener; John D Hayball
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.